



ALLIANCE™

[.https://www.globalseafood.org](https://www.globalseafood.org)

Intelligence

Australian biotech company launches early detection technology for shrimp diseases

12 January 2024

By Responsible Seafood Advocate

A single test can accurately detect 18 shrimp diseases and identify genetic variations

Genics, an Australian biotech firm, launched Shrimp MultiPath2.0 – an advanced technology for the early detection of shrimp diseases.

The technology differs from traditional kits and services by enabling the identification of 18 shrimp pathogens in a single test, as opposed to just one pathogen per sample. Shrimp MultiPath2.0 not only provides highly accurate detection of various diseases but also distinguishes between genetic subvariants of major pathogens, ensuring comprehensive protection for farmers.

“Genics Shrimp MultiPath2.0 acts as an early warning system, alerting farmers to the presence of pathogens weeks before any visible signs of illness appear in their animals,” Genics stated in a release. “This proactive approach is invaluable in preventing costly stock losses and maintaining the health of the aquaculture environment.”

“In the case of infectious hypodermal and hematopoietic necrosis virus (IHHNV), Shrimp MultiPath2.0



Genics, an Australian biotech firm, has launched Shrimp MultiPath2.0 – an advanced technology for the early detection of shrimp diseases. Photo courtesy of Genics.

can significantly increase farm gate value by up to US \$52,000.00 per hectare. For devastating pathogens like white spot syndrome virus (WSSV) and IMNV, Shrimp MultiPath2.0 has the potential to save entire harvests, sparing farmers from substantial financial setbacks.”

A comprehensive solution for the wild seafood supply chain.

- ✓ Crew rights
- ✓ Food safety
- ✓ Environmental responsibility

Best Seafood Practices

LEARN MORE >

[\(https://bspcertification.org/\)](https://bspcertification.org/)



Minutes, not days: Partnership takes aim at rapid tests for shrimp diseases

With USDA research funding, Sherlock Biosciences and the Gloucester Marine Genomics Institute will commercialize diagnostic tests for shrimp diseases.



Global Seafood Alliance

The technology detects a broad spectrum of pathogens, focusing on the most economically damaging. This comprehensive, targeted approach enables farmers to defend against the most critical disease threats efficiently.

Moreover, Shrimp MultiPath2.0 includes control tests that validate the integrity of DNA and RNA in every sample, setting the bar higher than industry standards. This precision is particularly crucial for shrimp, which contain PCR inhibitors like chitin.

“Shrimp MultiPath2.0 is a genuine innovation in shrimp pathogen detection, addressing the industry’s need for a comprehensive, fast and accurate testing solution,” wrote Genics. “With its ability to detect a wide range of pathogens, deliver swift results and provide secure, verified quantitative data, Shrimp MultiPath2.0 sets a new standard for certainty and safety.”

[@GAA_Advocate](https://twitter.com/GAA_Advocate) (https://twitter.com/GAA_Advocate).

Author



RESPONSIBLE SEAFOOD ADVOCATE

editor@globalseafood.org (<mailto:editor@globalseafood.org>).

Copyright © 2024 Global Seafood Alliance

All rights reserved.